Macquarie Group
CRBP icon

Macquarie Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Macquarie Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-507
Closed -$20 – 1947
2024
Q1 		$20 Buy
+507
New +$12.5K ﹤0.01% 1690
2020
Q4 		– Sell
-85
Closed -$5K – 2359
2020
Q3 		$5K Hold
85
– – ﹤0.01% 2335
2020
Q2 		$21K Buy
+85
New +$17.2K ﹤0.01% 2151
2018
Q1 		– Sell
-40
Closed -$9K – 2204
2017
Q4 		$9K Buy
+40
New +$8.56K ﹤0.01% 2272

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group's CRBP Position: Q2 2024 in Review

Macquarie Group sold out of Corbus Pharmaceuticals (CRBP) in Q2 2024, closing a stake of 507 shares — an estimated $20 sold.

Macquarie Group first reported a position in CRBP in Q4 2017 and held it in 4 quarters. The position peaked at $21K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2024.

  • Macquarie Group reported no remaining Corbus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 507 Corbus Pharmaceuticals shares in Q2 2024, an estimated $20.
  • Macquarie Group first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Macquarie Group's Corbus Pharmaceuticals position peaked at $21K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.